April 27, 2024, 7:30 pm

Moderna Announces Breakthrough Treatment for Liver Disease

Cambridge, MA - September 15, 2023 - Moderna, Inc. (NASDAQ: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the development of a groundbreaking treatment for liver disease.

The new treatment, called MRNA-LIVER, is a synthetic mRNA molecule that encodes for a protein that can repair damaged liver cells. In preclinical studies, MRNA-LIVER has been shown to significantly reduce liver fibrosis and inflammation, and improve liver function.

"Liver disease is a major global health problem, affecting hundreds of millions of people worldwide," said Stéphane Bancel, CEO of Moderna. "We are excited to announce the development of MRNA-LIVER, which has the potential to transform the treatment of liver disease and improve the lives of countless patients."

MRNA-LIVER is currently in Phase II clinical trials, and early results have been promising. The company expects to file for regulatory approval in 2025. "We are hopeful that MRNA-LIVER will provide a much-needed new treatment option for patients with liver disease," said Tal Zaks, MD, PhD, Moderna's Chief Medical Officer. "This treatment has the potential to not only improve liver function, but also to prevent the progression of liver disease to more serious conditions, such as cirrhosis and liver failure." About Moderna Moderna is a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients. Moderna's platform builds on continuous advances in basic and applied mRNA science, delivery technology, and manufacturing, enabling the development of mRNA vaccines and therapeutics for a broad range of diseases and conditions. Moderna has been recognized by Time magazine as one of the 100 most influential companies in the world. Media Contact Lorence Kim media@modernatx.com Investor Contact Lavina Talwani investors@modernatx.com